Join

Compare · ACAD vs JNJ

ACAD vs JNJ

Side-by-side comparison of ACADIA Pharmaceuticals Inc. (ACAD) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACAD and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • JNJ is the larger of the two at $560.33B, about 151.8x ACAD ($3.69B).
  • Over the past year, ACAD is down 3.3% and JNJ is up 49.9% - JNJ leads by 53.2 points.
  • ACAD has been more active in the news (9 items in the past 4 weeks vs 7 for JNJ).
  • Both have 25 recent analyst ratings on file.
PerformanceACAD-3.32%JNJ+49.92%
2025-06-09+0.00%2026-06-05
MetricACADJNJ
Company
ACADIA Pharmaceuticals Inc.
Johnson & Johnson
Price
$21.56-0.71%
$232.71+1.95%
Market cap
$3.69B
$560.33B
1M return
+0.47%
+3.67%
1Y return
-3.32%
+49.92%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
1985
News (4w)
9
7
Recent ratings
25
25
ACAD

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

JNJ

Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Latest ACAD

Latest JNJ